HomeAI · summaries
Storia in 5 fonti
What's Going On With Jazz Pharmaceuticals Stock Tuesday? - Jazz Pharmaceuticals (NASDAQ:JAZZ)
FDA approves Jazz Pharmaceuticals' Ziihera combinations for first-line treatment of HER2-positive gastroesophageal adenocarcinoma.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
New Jazz cancer drug approval could drive blockbuster sales
Ziihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramatically expanding the drug’s market potential.
- ·
healio.com
FDA approves Ziihera combinations for gastroesophageal adenocarcinoma
The FDA approved two zanidatamab-hrii-based regimens as first-line treatment for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal…
